Shattuck Labs Receives $10 Price Target from Analysts

Biotech firm focused on opioid addiction vaccines sees positive analyst outlook.

Mar. 16, 2026 at 8:08am

Got story updates? Submit your updates here. ›

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have received an average 'Moderate Buy' recommendation from eight research firms covering the company, with a consensus price target of $10.50. The biotech firm is developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial focus on opioids like fentanyl.

Why it matters

Shattuck Labs' work on opioid addiction vaccines is significant given the ongoing opioid crisis in the United States. If successful, their treatments could provide a new tool to combat overdoses and help those struggling with opioid dependence. The positive analyst outlook suggests the market sees promise in the company's approach.

The details

The analysts' ratings include one 'sell', one 'hold', and six 'buy' recommendations. Price targets range from $4 to $15, with the average at $10.50. Wedbush raised its target from $4 to $8 and upgraded the stock to 'outperform', while HC Wainwright upgraded it to 'buy' with a $6 target. Piper Sandler initiated coverage with an 'overweight' rating and $15 target.

  • Shattuck Labs reported Q4 2025 earnings on March 5, 2026.

The players

Shattuck Labs, Inc.

A clinical-stage biotechnology company headquartered in Cambridge, Massachusetts that is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids.

Wedbush

An investment firm that raised its price target on Shattuck Labs from $4 to $8 and upgraded the stock to 'outperform'.

HC Wainwright

An investment firm that upgraded Shattuck Labs from 'neutral' to 'buy' with a $6 price target.

Piper Sandler

An investment firm that initiated coverage of Shattuck Labs with an 'overweight' rating and $15 price target.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Shattuck Labs' work on opioid addiction vaccines is seen as promising by analysts, who have issued a consensus 'Moderate Buy' rating and an average $10.50 price target on the stock. If successful, the company's treatments could provide a new tool to combat the ongoing opioid crisis in the United States.